James Czirr Net Worth

The estimated Net Worth of James C Czirr is at least $24.4 Millón dollars as of 22 April 2024. Mr. Czirr owns over 25,000 units of Galectin Therapeutics Inc stock worth over $16,226,847 and over the last 13 years he sold GALT stock worth over $8,065,711. In addition, he makes $134,284 as Director at Galectin Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Czirr GALT stock SEC Form 4 insiders trading

James has made over 16 trades of the Galectin Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 25,000 units of GALT stock worth $76,500 on 22 April 2024.

The largest trade he's ever made was exercising 500,000 units of Galectin Therapeutics Inc stock on 27 January 2014 worth over $1,500,000. On average, James trades about 70,867 units every 136 days since 2011. As of 22 April 2024 he still owns at least 5,922,207 units of Galectin Therapeutics Inc stock.

You can see the complete history of Mr. Czirr stock trades at the bottom of the page.

James Czirr biography

James C. Czirr serves as Director of the Company. Mr. Czirr has served as a director since February 2009, served as Chairman of the Board from February 2009 until January 2016 and Executive Chairman from February 2010 until January 2016, is a co-founder of 10X Fund, L.P. and is a managing member of 10X Capital Management LLC, the general partner of 10X Fund, L.P. Mr. Czirr was a co-founder of Galectin Therapeutics in July 2000. Mr. Czirr was instrumental in the early stage development of Safe Science Inc., a developer of anti-cancer drugs; served from 2005 to 2008 as Chief Executive Officer of Minerva Biotechnologies Corporation, a developer of nano particle bio chips to determine the cause of solid tumors; and was a consultant to Metalline Mining Company Inc., now known as Silver Bull Resources, Inc., (AMEX: SVBL), a mineral exploration company seeking to become a low cost producer of zinc. Mr. Czirr received a B.B.A. degree from the University of Michigan.

What is the salary of James Czirr?

As the Director of Galectin Therapeutics Inc, the total compensation of James Czirr at Galectin Therapeutics Inc is $134,284. There are 12 executives at Galectin Therapeutics Inc getting paid more, with Harold Shlevin having the highest compensation of $1,306,510.

How old is James Czirr?

James Czirr is 66, he's been the Director of Galectin Therapeutics Inc since 2016. There are 5 older and 14 younger executives at Galectin Therapeutics Inc. The oldest executive at Galectin Therapeutics Inc is Gilbert Omenn, 79, who is the Independent Director.

What's James Czirr's mailing address?

James's mailing address filed with the SEC is 4908 S. ASHTON CT., , SPOKANE,, WA, 99223.

Insiders trading at Galectin Therapeutics Inc

Over the last 13 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr y Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.

What does Galectin Therapeutics Inc do?

galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much

Complete history of Mr. Czirr stock trades at Galectin Therapeutics Inc

Galectin Therapeutics Inc executives and stock owners

Galectin Therapeutics Inc executives and other stock owners filed with the SEC include:

• Harold Shlevin,
  Director
• Jack Callicutt,
  Chief Financial Officer, Secretary
• Dr. Pol F. Boudes M.D., Ph.D.,
  Chief Medical Officer
• Dr. Pol F. Boudes,
  Chief Medical Officer
• Joel Lewis,
  Pres, CEO & Director
• Kevin Freeman,
  Independent Director
• Joel Lewis,
  President, Chief Executive Officer, Director
• Richard Uihlein,
  Independent Chairman of the Board
• Gilbert Amelio,
  Independent Director
• Gilbert Omenn,
  Independent Director
• Kary Eldred,
  Independent Director
• Eliezer Zomer,
  Executive Vice President - Manufacturing and Product Development
• Marc Rubin,
  Independent Director
• James Czirr,
  Director
• Richard Zordani,
  Independent Director
• Elissa Schwartz,
  Independent Director
• Pol Boudes,
  Chief Medical Officer
• J. Rex Horton,
  Executive Director - Regulatory Affairs and Quality Assurance
• Adam Allgood,
  Executive Director of Clinical Development
• Beth Knowles,
  Exec. Assistant & Officer Mang.
• Robert Tritt,
  Gen. Counsel
• Jack W. Callicutt CPA, CPA,
  CFO, Treasurer & Sec.
• Theodore Daniel Zucconi,
  Director
• John F Mauldin,
  Director
• Fund, L.P.10 X Capital Mana...,
  
• Steven Prelack,
  Director
• Arthur Greenberg,
  Director
• Khurram Jamil,
  Chief Medical Officer
• Benjamin Sr Carson,
  
• Stephen Shulman,
  Director
• Fund, L.P.10 X Capital Mana...,
  
• Peter G Traber,
  CEO and President
• Herman Paul Pressler,
  Director
• Thomas Mcgauley,
  Chief Financial Officer
• Rod D Martin,
  Director
• Jerald K Rome,
  Director
• Fund, L.P.Czirr James C10 X...,